Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to Post FY2028 Earnings of $14.47 Per Share, Wedbush Forecasts

Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) – Stock analysts at Wedbush issued their FY2028 EPS estimates for shares of Neurocrine Biosciences in a note issued to investors on Monday, January 29th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of $14.47 for the year. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $2.16 per share.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $0.91 by ($0.09). The business had revenue of $498.80 million for the quarter, compared to the consensus estimate of $479.09 million. Neurocrine Biosciences had a net margin of 10.71% and a return on equity of 10.54%. The firm’s revenue for the quarter was up 28.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 EPS.

A number of other research firms also recently weighed in on NBIX. Wells Fargo & Company raised their price target on shares of Neurocrine Biosciences from $110.00 to $127.00 and gave the company an “equal weight” rating in a report on Wednesday, December 13th. The Goldman Sachs Group lifted their target price on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Piper Sandler lifted their target price on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the stock a “neutral” rating in a report on Wednesday, November 1st. Raymond James lifted their target price on shares of Neurocrine Biosciences from $135.00 to $145.00 and gave the stock an “outperform” rating in a report on Wednesday, November 1st. Finally, Mizuho dropped their target price on shares of Neurocrine Biosciences from $116.00 to $114.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $134.69.

Check Out Our Latest Report on Neurocrine Biosciences

Neurocrine Biosciences Trading Down 1.6 %

Neurocrine Biosciences stock opened at $139.77 on Wednesday. The company has a market capitalization of $13.73 billion, a P/E ratio of 75.15, a P/E/G ratio of 0.76 and a beta of 0.33. The firm’s fifty day simple moving average is $127.79 and its 200-day simple moving average is $115.42. Neurocrine Biosciences has a 1-year low of $89.04 and a 1-year high of $143.35.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth approximately $27,000. Headinvest LLC acquired a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $28,000. KB Financial Partners LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth approximately $32,000. BluePath Capital Management LLC acquired a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $35,000. Finally, Covestor Ltd lifted its position in shares of Neurocrine Biosciences by 431.0% during the first quarter. Covestor Ltd now owns 377 shares of the company’s stock worth $35,000 after purchasing an additional 306 shares in the last quarter. 93.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $139.86, for a total value of $1,398,600.00. Following the transaction, the insider now directly owns 35,882 shares in the company, valued at $5,018,456.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $139.86, for a total value of $1,398,600.00. Following the transaction, the insider now directly owns 35,882 shares in the company, valued at $5,018,456.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Kevin Charles Gorman sold 105,835 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $132.44, for a total transaction of $14,016,787.40. Following the completion of the transaction, the chief executive officer now owns 499,754 shares in the company, valued at $66,187,419.76. The disclosure for this sale can be found here. Insiders have sold a total of 265,184 shares of company stock worth $34,277,341 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Articles

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.